Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) EBITDA Margin: 2016-2024

Historic EBITDA Margin for Summit Therapeutics (SMMT) over the last 4 years, with Dec 2024 value amounting to 679,777.78%.

  • Summit Therapeutics' EBITDA Margin was N/A to 679,777.78% in Q4 2024 from the same period last year, while for Dec 2024 it was 2,544.92%, marking a year-over-year change of. This contributed to the annual value of 2,546.07% for FY2024, which is 143506.00% down from last year.
  • Summit Therapeutics' EBITDA Margin amounted to 679,777.78% in Q4 2024, which was up 29,655.36% from 2,284.56% recorded in Q3 2024.
  • Summit Therapeutics' 5-year EBITDA Margin high stood at 679,777.78% for Q4 2024, and its period low was -9,742.73% during Q3 2022.
  • In the last 2 years, Summit Therapeutics' EBITDA Margin had a median value of 1,945.04% in 2024 and averaged 135,131.52%.
  • Data for Summit Therapeutics' EBITDA Margin shows a peak YoY skyrocketed of 52,118bps (in 2020) over the last 5 years.
  • Quarterly analysis of 3 years shows Summit Therapeutics' EBITDA Margin stood at 1,946.25% in 2020, then followed by -9,742.73% in 2022, then followed by 679,777.78% in 2024.
  • Its EBITDA Margin was 679,777.78% in Q4 2024, compared to 2,284.56% in Q3 2024 and 1,945.04% in Q2 2024.